Cigarette smoking in the United States causes serious illnesses among an estimated 8.6 million persons (1) and approximately 440,000 deaths annually (2), resulting in $157 billion in health-related economic costs (2). To reduce smoking prevalence, morbidity, mortality, and economic impact, state tobacco-control programs should include interventions to help persons stop smoking (3). To assess the prevalence of current cigarette smoking among adults, attempts to quit, and receipt of physician advice to quit during the preceding year, CDC analyzed data from the 2002 Behavioral Risk Factor Surveillance System (BRFSS) survey. This report summarizes the results of that analysis, which indicated a threefold difference in smoking prevalence across the 50 states, the District of Columbia (DC), Guam, Puerto Rico, and the U.S. Virgin Islands (range: 9.5%-32.6%) ( Figure) . To support smokers' attempts to quit, states/areas should implement comprehensive tobacco-control programs that include interventions to help persons stop smoking (e.g., quitlines).
Cigarette smoking in the United States causes serious illnesses among an estimated 8.6 million persons (1) and approximately 440,000 deaths annually (2) , resulting in $157 billion in health-related economic costs (2) . To reduce smoking prevalence, morbidity, mortality, and economic impact, state tobacco-control programs should include interventions to help persons stop smoking (3) . To assess the prevalence of current cigarette smoking among adults, attempts to quit, and receipt of physician advice to quit during the preceding year, CDC analyzed data from the 2002 Behavioral Risk Factor Surveillance System (BRFSS) survey. This report summarizes the results of that analysis, which indicated a threefold difference in smoking prevalence across the 50 states, the District of Columbia (DC), Guam, Puerto Rico, and the U.S. Virgin Islands (range: 9.5%-32.6%) (Figure) . To support smokers' attempts to quit, states/areas should implement comprehensive tobacco-control programs that include interventions to help persons stop smoking (e.g., quitlines).
BRFSS is a state-based, random-digit-dialed telephone survey of the noninstitutionalized, civilian U.S. population aged >18 years. Because BRFSS data are state-specific, median prevalences were reported rather than national averages. Estimates were weighted by age, race/ethnicity, and sex distribution of each state's population, and 95% confidence intervals were calculated by using SUDAAN. The median response rate across states/areas was 58.3% (range: 42.2%-82.6%).
Current cigarette smoking status was determined by asking respondents, "Have you smoked at least 100 cigarettes in your entire life?" and "Do you now smoke cigarettes every day, some days, or not at all?" Current smokers were defined as those who reported having smoked >100 cigarettes during their lifetimes and who currently smoke every day or some days. Attempted smoking cessation was assessed by asking every day smokers, "During the past 12 months, have you stopped 
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implemented by certain states. In addition, the proportion of current smokers who had been advised to quit was 72.0%, which was higher than estimates from other surveys (5), although comparisons are limited by the number of states that asked the question. This increase might reflect efforts within health-care systems to increase treatment for tobacco users through proven interventions and system-level changes (e.g., physician reminders to provide counseling). The increases also might be attributed to expanded tobacco-control programs at the state level, including the expansion of evidence-based, telephone quitline services (6) . During 1992-2002, states offering some form of quitline services increased from one to 32. Physicians often lack the time and often are not comfortable providing cessation counseling. Establishing readily accessible, free counseling services (e.g., quitlines) increases the availability of more intensive cessation assistance and might also encourage health-care providers to assess tobacco use and provide both advice to quit and medication (7) . The findings in this report are subject to at least three limitations. First, BRFSS does not sample persons in households without telephones. Second, response rates might have affected estimates; however, BRFSS estimates are comparable with current smoking estimates obtained from other surveys with higher response rates (8) . Finally, data were based on selfreports, and smoking status in BRFSS is not validated by biochemical markers. However, BRFSS data on cigarette smoking measures have moderate-to-high validity and high reliability (9) , and self-reports of smoking have been found to be valid in other population-based surveys (10) .
To help states plan and implement comprehensive tobaccocessation programs, CDC recommends several strategies, including implementing telephone quitlines, integrating tobacco cessation into routine health-care delivery, and making tobacco-treatment services a standard health benefit (3) . Approximately 70% of smokers visit physicians each year (5), giving health-care providers the opportunity to reach smokers. Through these interactions, providers can advise smokers to quit, discuss appropriate treatments (e.g., medications and counseling), and provide referrals to quitlines or other community programs.
To implement tobacco-control programs fully and reduce smoking prevalence further, CDC recommends spending $7-$20 per capita in smaller states (i.e., population of <3 million), $6-$17 per capita in medium-sized states (i.e., population of 3-7 million), and $5-$16 per capita in larger states (i.e., population of >7 million) (3). In 2002, per capita funding varied across states (range: $0.33-$19.16); few met CDC's minimum funding recommendations (4) . In recent years, states have received less funding for tobacco-control programs, which inhibits expansion of cessation activities such as quitlines and implementation of recommended changes within the healthcare system. Unless states expand cessation and other tobaccocontrol efforts, the 2010 national health objective of reducing smoking prevalence to <12% will not be achieved.
Bovine Spongiform Encephalopathy in a Dairy CowWashington State, 2003
On December 23, 2003, the U.S. Department of Agriculture (USDA) made a preliminary diagnosis of bovine spongiform encephalopathy (BSE) in a single "downer" (i.e., nonambulatory disabled) dairy cow in Washington state. On December 25, this diagnosis was confirmed by the BSE international reference laboratory in Weybridge, England. This report summarizes the findings of the initial investigation of this case and describes the public health prevention measures adopted by USDA to protect the human food supply. The occurrence of BSE in the United States reinforces the need for physicians to be aware of the clinical features of variant Creutzfeldt-Jakob disease (vCJD) and to arrange for brain autopsies in all decedents with suspected or probable CJD to assess the neuropathology of these patients.
The BSE-positive cow was aged 6.5 years when it was slaughtered on December 9. Before slaughter, the cow was nonambulatory; its condition was attributed to complications from calving. The animal was examined by a USDA Food Safety and Inspection Service (FSIS) veterinary medical officer both before and after slaughter. After examination, the carcass was released for use as food for human consumption. Tissues (e.g., brain, spinal cord, and small intestine) considered to be at high risk for the transmission of the BSE agent were removed from the cow during slaughter and sent for inedible rendering (often used for nonruminant animal feed). Because the cow was nonambulatory at slaughter, brain tissue samples were taken by USDA's Animal and Plant Health Inspection Service (APHIS) as part of its targeted surveillance for BSE. On December 23, a presumptive diagnosis of BSE was made, and the herd to which this cow belonged was placed under a state hold order. USDA, in collaboration with state and other federal animal and public health agencies, industry representatives, and the Canadian Food Inspection Agency (CFIA), initiated investigations of potentially exposed cattle and regulated products.
On December 24, FSIS recalled beef from cattle slaughtered in the same plant on the same day as the BSE-positive cow. Some of the beef subject to the recall had been shipped to several establishments, which processed it further. Meat products manufactured from the recalled meat were distributed primarily to locations in Oregon and Washington, with smaller quantities distributed to locations in California, Idaho, Montana, and Nevada. FSIS continues to verify the distribution and control of all recalled products.
The U.S. Food and Drug Administration (FDA) and inspectors from Oregon and Washington have located all known potentially infectious rendered products from the BSEpositive cow. The rendering plants that processed this material have placed a voluntary hold on all known potentially infectious products, none of which had left the control of the companies or entered commercial distribution as of January 7, 2004 . FDA continues its investigation of all regulated products related to the BSE-positive cow.
APHIS, in collaboration with CFIA, traced the birth of the BSE-positive cow to a farm in Alberta, Canada. On January 6, USDA and CFIA announced that DNA evidence had confirmed this traceback to Canada with a high degree of certainty. This line of investigation indicates that the BSE-positive cow was one of 82 animals from a Canadian herd cleared for shipment to the United States; 81 of the cattle listed on the Canadian animal health certificate entered the United States on September 4, 2001, through Oroville, Washington. These cattle are being traced to determine their disposition or current location. The BSE-positive cow gave birth to two live calves while in the United States. The first is a yearling heifer on the same farm as the BSE-positive cow. The second, a bull calf, was in a group of calves at another location, a calffeeding operation that also was under a state hold order. Because the bull calf could not be identified definitively, APHIS completed the elimination of all calves at this site on January 6. Since the epidemiologic investigation began, APHIS has developed criteria for determining additional cattle at risk for BSE that should be eliminated.
On December 30, USDA announced additional safeguards to further minimize the risk for human exposure to BSE in the United States (Box). Beginning immediately, FSIS has prohibited the use of downer cattle for food for human consumption. Through its emergency rule-making powers, FSIS will take additional actions that will become effective on their publication. Planned actions include the required removal of "specified risk materials" (i.e., high-risk materials) from announced an immediate ban on the use of nonambulatory disabled ("downer") cattle for human food consumption.
• FSIS inspectors will not mark cattle carcasses tested for BSE as "inspected and passed" until negative test results are received.
• FSIS will prohibit the use in the human food supply (including advanced meat recovery [AMR]*) of "specified risk materials" (i.e., high-risk materials), including the skull, brain, trigeminal ganglia, eyes, vertebral column, spinal cord, and dorsal root ganglia of cattle aged >30 months and the tonsils and small intestine of cattle of all ages.
• FSIS also will prohibit the presence of brain, spinal cord, trigeminal ganglia, and dorsal root ganglia from cattle aged <30 months in meat produced by AMR.
• To reduce the risk that portions of the brain are not dislocated into the tissues of the carcass as a consequence of stunning cattle before slaughter, FSIS will ban airinjection stunning.
• FSIS will prohibit the use of mechanically separated beef † in the human food supply.
*An industrial process that removes muscle tissue from the bone of beef carcasses under high pressure without incorporating bone material when operated properly; product may be labeled as "meat." † A meat food product that is finely ground to a paste-or batter-like consistency and that results from the mechanical separation and removal of most of the bones from the attached skeletal muscle of cattle carcasses and parts of carcasses; may not be labeled as "meat" but rather as "meat food product." animals aged >30 months at the time of slaughter and withholding the USDA "inspected and passed" mark until negative BSE test results are received for any animal tested. To enhance the speed and accuracy of the response to animal health threats such as BSE, APHIS is working to implement a national identification system to track animals of various species through the livestock marketing chain. USDA also will appoint an international panel of scientists with BSE expertise to provide an objective review of the response to the identification of the BSE-positive cow described in this report and to identify areas for potential improvement of current BSE safeguards. Editorial Note: BSE is a progressive, fatal neurologic disorder of cattle and is classified as one of the transmissible spongiform encephalopathies, a group of diseases of animals and humans believed to be caused by abnormally folded proteins called prions. BSE was first identified in 1986 in the United Kingdom (UK), where it caused a large outbreak among cattle (1) . Although the source of the BSE epizootic agent is uncertain, feeding cattle BSE-contaminated meat-andbone meal is the major contributory factor to the amplification of BSE among cattle (2). Since 1986, BSE cases have been identified in 20 European countries, Japan, Israel, and Canada. Since BSE surveillance was initiated in the United States in 1990, USDA has tested brain tissue from approximately 57,000 cattle, targeting those at high risk for BSE (e.g., downer cattle and cattle with neurologic signs); the case described in this report represents the first identification of BSE in the United States. Whether an epidemiologic link exists between this BSE case traced to Canada and the previous case reported in Canada is not known.
Epidemiologic and laboratory evidence suggests that the BSE agent has been transmitted to humans via consumption of BSE-contaminated cattle products, causing vCJD (1). However, the risk for acquiring vCJD from consumption of BSEcontaminated product is low, presumably because of a "species barrier" that provides substantial but incomplete protection against development of vCJD. In the UK, where an estimated one million or more cattle probably were infected with BSE, cases of vCJD continue to be reported; however, the number of cases of vCJD remains small, with 148 probable and confirmed vCJD cases identified as of January 7, including those of three persons residing in Ireland, Canada, and the United States who are believed to have been exposed to BSE in the UK (1, 3) . Seven additional cases not directly linked to the BSE outbreak in the UK also have been reported (six in France and one in Italy).
In the United States, the feeding of rendered cattle products to other cattle has been prohibited since 1997, and the importation of cattle and cattle products from countries with BSE or considered to be at high risk for BSE has been prohibited since 1989; these measures have minimized the potential exposure of animals and humans to the BSE agent (4). The additional safeguards described in this report should further reduce the risk for acquiring vCJD.
Substantial clinical and epidemiologic differences exist between vCJD and the more commonly occurring classic form of CJD recognized in the United States for decades before the emergence of BSE (Table) . Although strong epidemiologic and laboratory evidence indicates that vCJD is linked causally with BSE, no exogenous source of infection has been identified for approximately 85% of classic CJD cases (5). The median age at death of classic CJD patients in the United States is 68 years, compared with 28 years for vCJD patients. The age ('tr st-"w r-the) e e distribution of these deaths illustrates that most vCJD occurs in age groups in which classic CJD is rare ( Figure) (RG Will, M.D., National CJD Surveillance Unit, Edinburgh, Scotland, personal communication, 2004). In addition, the median duration of illness before death for classic CJD patients in the United States is 4-5 months, compared with 13-14 months for vCJD patients (6) . Patients with vCJD often have prominent early behavioral or psychiatric manifestations and painful sensory symptoms, with neurologic signs such as myoclonus and extrapyramidal dysfunction being delayed for several months after illness onset (6) . The characteristic electroencephalographic pattern of periodic sharp waves observed in classic CJD patients is absent in patients with vCJD. A characteristic high signal in the posterior thalamus on T2-and diffusion-weighted magnetic resonance imaging (the "pulvinar sign") is demonstrated in >75% of vCJD patients, and in the appropriate clinical context, is highly indicative of a vCJD diagnosis (7) . Confirmatory diagnosis of vCJD and classic CJD requires pathologic examination of brain tissue obtained at autopsy or biopsy. The neuropathology in vCJD is distinguished by the presence of numerous deposits of kuru-type plaques surrounded by vacuoles (i.e., "florid plaques") in the cerebellum and cerebrum and the marked accumulation of the pathologic protease-resistant prion protein on immunohistochemical (IHC) analysis (8) . Prions are detected readily by IHC analysis in lymphoid tissues (e.g., appendix, lymph nodes, spleen, and tonsils) of vCJD patients, but not in classic CJD patients (9) . All persons with vCJD tested as of January 2004 have had methionine homozygosity at the polymorphic codon 129 of the prion protein gene, indicating that persons who do not carry this genotype (comprising the majority of the general population) appear to have increased resistance to vCJD.
Since 1996, CDC has used several mechanisms to conduct surveillance for classic CJD and vCJD in the United States (10) . CDC reviews national multiple cause-of-death data to monitor the epidemiology of CJD in the United States. CDC, in collaboration with state and local health departments, investigates CJD cases in persons aged <55 years to identify cases of possible vCJD. In addition, CDC assists routinely in the investigation of suspected cases of vCJD spontaneously reported by health-care providers. During 1996-1997, in collaboration with the American Association of Neuropathologists, CDC established the National Prion Disease Pathology Surveillance Center (NPDPSC) at Case Western Reserve University, Cleveland, Ohio. NPDPSC provides advanced neuropathologic and biochemical diagnostic services free of charge to U.S. physicians and state and local health departments. These surveillance efforts have not detected any cases of indigenous vCJD in the United States.
The emergence of BSE in the United States reinforces the need for physicians to be aware of the clinical features of vCJD in all patients, regardless of age, who report with distinguishing characteristics (Table 2) . Because testing brain tissue permits the most definitive diagnosis of all forms of CJD and identification of emerging forms of the disease, including vCJD, CDC encourages physicians to arrange for brain autopsies in all decedents with suspected or diagnosed CJD and to use the free services of NPDPSC to assess the neuropathology of these patients. Information about these services is available from NPDPSC at http://www.cjdsurveillance.com or from CDC, telephone 404-639-3091. Respiratory diphtheria can be severe or fatal in unvaccinated persons; even with appropriate treatment, 5%-10% of patients with diphtheria die (1). For >50 years, vaccination against diphtheria has been recommended for children and adults in the United States. Persons who are unvaccinated or vaccinated inadequately can contract diphtheria during travel to areas where the disease is endemic*, putting them and their close contacts at risk for severe illness. This report describes fatal respiratory diphtheria in an unvaccinated Pennsylvania resident who had visited Haiti, a country where the disease is endemic. The case highlights the need for all international travelers to be up-to-date with all recommended vaccinations, including a primary series of diphtheria toxoid-containing vaccine.
In October 2003, the Pennsylvania Department of Health and CDC were notified of a suspected case of respiratory diphtheria in a previously healthy Pennsylvania man aged 63 years who reported that he had never been vaccinated against diphtheria. He and seven other men from New York, Pennsylvania, and West Virginia had returned from a week-long trip to rural Haiti, where they helped build a church. One day before leaving Haiti, the patient had a sore throat. Two days after his return to Pennsylvania, he visited a local emergency department (ED) complaining of a persistent sore throat and difficulty swallowing. A rapid test for group A streptococcal antigens and a test for heterophile agglutinins were negative; he received oral amoxicillin and clavulanate potassium.
On the fourth day of illness, the patient returned to the ED with chills, sweating, restlessness, difficulty swallowing and breathing, nausea, and vomiting. On examination, he was afebrile and had stridor and a swollen neck. Expiratory wheezing and diminished breath sounds in the left lung base were noted. Arterial pO2 was 88% on room air. Radiographs of the neck and chest showed prevertebral soft-tissue swelling, enlargement of the epiglottis, and opacity of the left lung base. Initial diagnosis was acute epiglottitis with airway obstruction and impending respiratory failure. The patient was admitted to the intensive care unit; during intubation, a laryngoscopy was performed that revealed a yellow exudate on the tonsils, posterior pharynx, and soft palate, and sloughing of the anterior pharyngeal folds. During the next 4 days, the patient was treated with azithromycin, ceftriaxone, nafcillin, and steroids, but he became hypotensive and febrile (100.9° F [38.3° C]). Methicillin-susceptible Staphylococcus aureus was isolated from sputum. Culture of a throat swab specimen was negative for Corynebacterium diphtheriae.
On the eighth day of illness, the patient was transferred to a tertiary care facility. A chest radiograph showed infiltrates in the right and left lung bases. During tracheostomy, a white exudate consistent with C. diphtheriae infection was observed. The pseudomembrane covered the supraglottic structures, including the epiglottis, vallecula and piriform sinus, the postcricoid region, and glottic inlet. Gram stain of laryngeal exudates showed gram-positive rods, gram-positive cocci, and yeast. The patient continued to receive multiple antibiotics, including penicillin, vancomycin, and gentamicin; diphtheria antitoxin (DAT) was administered on the ninth day of illness. Two days later, a sample of the pseudomembrane was negative by culture but positive for C. diphtheriae tox genes by polymerase chain reaction (PCR) performed at CDC. After 17 days of illness, the patient had cardiac complications and died. Based on the patient's travel to a country where diphtheria is endemic, the pattern of illness, and positive PCR results, his illness was consistent with a confirmed case of respiratory diphtheria.
Investigations of close contacts were conducted in New York, Pennsylvania, and West Virginia. Close contacts were defined as persons who had been exposed to the patient's respiratory secretions or who lived in the same household as the patient. These persons included his wife, health-care providers, Haiti traveling companions, and two other persons with whom he shared accommodations on the second day of his illness. Specimens were obtained for isolation of C. diphtheriae and PCR testing; all culture and PCR results were negative. Close contacts were administered antibiotic prophylaxis and offered a diphtheria toxoid-containing vaccine if they had not received a booster within the preceding 5 years. † Contact the duty officer for diphtheria antitoxin, telephone, 404-639-8257, Editorial Note: Diphtheria is caused by toxigenic strains of the bacterium C. diphtheriae and less frequently by C. ulcerans. Since universal vaccination began in the 1940s, diphtheria has been uncommon in the United States. In 2001, the vaccination coverage rate among children aged 19-35 months who had received >3 doses of diphtheria toxoid-containing vaccine was approximately 95% (2). However, among adults, coverage rates with decennial booster doses were lower. Testing of serum samples from participants in the Third National Health and Nutrition Examination Survey (1988) (1989) (1990) (1991) (1992) (1993) (1994) indicated that the percentage of U.S. residents with protective levels (>0.1 IU/ml) of diphtheria antibodies decreased progressively with age, from 91% at ages 6-11 years to approximately 30% at ages 60-69 years (3).
During 1980-2001, a total of 53 cases of probable or confirmed respiratory diphtheria were reported to CDC (4); the most recent previous report from Pennsylvania was in 1992. In recent years, sporadic cases of respiratory diphtheria have continued to occur in the United States, primarily among adults. In 1996, toxigenic C. diphtheriae was isolated from residents of an American Indian community (5), and toxigenic C. ulcerans was isolated from an Indiana resident aged 54 years who had respiratory diphtheria (6) . In 1999, a Washington state resident aged 75 years died from an illness clinically consistent with respiratory diphtheria; toxigenic C. ulcerans was isolated from a throat swab (7) .
Respiratory diphtheria should be suspected in patients with membranous nasopharyngitis or obstructive laryngotracheitis who returned recently from areas where the disease is endemic or who were in close contact with persons who returned recently from such areas. DAT, which is available from CDC † , should be administered as soon as diphtheria is suspected, without waiting for laboratory confirmation. Antibiotics are administered to patients suspected with diphtheria to eradicate carriage of C. diphtheriae (8) . Because diphtheria disease might not confer immunity, patients should be administered a diphtheria toxoid-containing vaccine during convalescence.
Diphtheria-infected travelers returning to the United States with incubating or untreated disease can transmit C. diphtheriae to their close contacts. Antibiotic prophylaxis is recommended for close contacts after nasal and pharyngeal specimens for culture are obtained (8) . Adolescent and adult contacts who have not received a dose of a diphtheria toxoidcontaining vaccine during the preceding 5 years should be vaccinated (8) . Children should receive diphtheria and tetanus toxoids and acellular pertussis vaccine at ages 2 months, 4 months, 6 months, 12-18 months, and 4-6 years; a booster dose of tetanus and diphtheria toxoids (Td) vaccine should be administered preferably at ages 11-12 years (or ages 13-18 years for catch-up); and protection should be maintained by a regular booster of Td every 10 years (9) .
In addition to taking destination-specific, diseaseprevention precautions, all international travelers, regardless of age or destination, should ensure that they are up-to-date with all recommended vaccinations, including a primary series (i.e., >3 doses) of diphtheria toxoid-containing vaccine that includes a dose within the preceding 10 years. Additional information on vaccines recommended for travelers can be obtained from state health departments or CDC (10).
Update: Influenza-Associated Deaths Reported Among Children Aged <18 Years -United States,
2003-04 Influenza Season
During the 2003-04 influenza season, CDC has received reports from state health departments regarding deaths among children with evidence of influenza virus infection. To help investigate these deaths, CDC has requested that all influenza-associated deaths among children aged <18 years be reported to CDC through state and local health departments during the 2003-04 season. This summary is based on preliminary data reported from 31 states as of January 6, 2004 , and updates a previous report published in MMWR (1).
Since October 2003, a total of 93 influenza-associated deaths among children aged <18 years have been reported to CDC. All patients had evidence of influenza virus infection detected by rapid antigen testing or other laboratory tests.
The date of death was reported for 92 of the 93 cases (Figure) . The median age of the 93 children was 4 years (range: 4 weeks-17 years), with 55 (59%) children aged <5 years and 24 (26%) aged 6-23 months (Table 1) . Among the 92 children whose sex was reported, 41 (45%) were male. A total of 35 (38%) of the 93 children were reported to have had underlying chronic medical conditions (Table 2) , and 41 (44%) were reported to have had no underlying conditions; the medical history was unknown for 17 (18%) children. Of the 55 children for whom the location of death was reported, 15 (27%) died at home, 12 (22%) died in emergency departments, 25 (45%) died as inpatients, and three (5%) died in transport to hospitals.
Pneumonia was a reported complication in 25 of the 93 children. Invasive bacterial co-infections were reported in 15 children, including methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus sp., Haemophilus influenzae (type b and non-typable), Neisseria meningitidis, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Serratia marcescens.
Of the 45 children whose influenza vaccination status was reported, one child had evidence of adequate vaccination, whereas 33 (73%) were not vaccinated, and six children were partially vaccinated (i.e., they had received 1 of 2 doses); five children were reported as vaccinated, but the interval between vaccination and onset of illness was not documented.
Influenza A viruses were isolated from respiratory specimens collected from 28 patients. A total of 55 children had influenza virus infection confirmed by rapid antigen testing and direct fluorescent antibody staining of respiratory specimens. Four additional children had influenza virus infection confirmed solely by reverse transcriptase polymerase chain reaction (RT-PCR) of respiratory specimens.
A total of 16 children with evidence of influenza virus infection by culture, rapid antigen detection test, or RT-PCR also had autopsy specimens tested at CDC by immunohistochemical (IHC) staining. Of these, 11 had influenza A viral antigen detected by IHC staining in respiratory epithelium of airway tissue specimens (2) . In addition, autopsy tissue specimens from four of 11 pediatric deaths without previous laboratory confirmation of influenza virus infection were positive by IHC staining for influenza A viral antigen.
Reported by: State and local health depts. Influenza Response Team; I Shui, MPH, Assoc of Schools of Public Health/CDC/ATSDR Internship Program; N Bhat, MD, M Glover, ScD, K Broder, MD, D Posey, MD, EIS officers, CDC.
Editorial Note: During October 11, 2003-January 6, 2004, a total of 93 influenza-associated deaths among children aged <18 years were reported to CDC. Of the 51 deaths that were not reported previously, 26 occurred before publication of the previous report (1) .
Because laboratory-confirmed influenza illnesses and deaths among children are not nationally reportable conditions, the numbers of deaths reported this season cannot be compared directly with previous influenza seasons, and the proportion of illnesses associated with death cannot be estimated. Heightened awareness of severe complications and deaths associated with influenza among children this season and increased testing might be contributing to identification of more pediatric fatalities related to influenza than in previous seasons.
These reports underscore the need to further characterize the impact of influenza among children. In addition to initiating voluntary reporting of influenza-associated deaths, CDC is developing studies in collaboration with health departments and other partners to estimate the rates of influenzaassociated hospitalization and serious complications and to identify risk factors for severe illness and complications during the current season. Additional studies are planned to assess the relative severity of this season by comparing influenza-associated hospitalizations and mortality among children with those in previous seasons. Such information might be helpful in evaluating current pediatric influenza vaccination recommendations.
Clinicians should consider influenza testing in children who have severe febrile illness, when influenza viruses are circulating in their local community. Clinicians should recognize that secondary conditions such as bacterial infection can complicate some cases of influenza. Susceptibility testing of bacterial isolates is important to guide appropriate antibiotic therapy. Guidelines for antiviral treatment of influenza have been published (3).
CDC Request for Reports of InfluenzaAssociated Deaths Among Children
During the 2003-04 influenza season, CDC is requesting that all influenza-associated deaths among children aged <18 years be reported to CDC through state and local health departments. In addition, CDC is requesting submission of postmortem tissue specimens and autopsy reports when available. Influenza viral isolates in fatal cases also should be sent to CDC for antigenic characterization.
To report the influenza-associated death of a child aged <18 years, state and local health departments should contact CDC's Influenza Branch, telephone, 800-232-4636; e-mail, eocinfluenza@cdc.gov. Case reporting forms are available to state and local health departments and medical examiners via the Epidemic Information Exchange (Epi-X), accessible at http://www.cdc.gov/mmwr/epix/epix.html. Completed forms should be sent to CDC with a cover sheet with the heading, "ATTN: Fatal Case Reporting" via fax, 888-232-1322.
Update: Influenza ActivityUnited States, December 21, 2003-January 3, 2004
The number of states reporting widespread influenza activity* decreased during December 21, 2003-January 3, *Levels of activity are 1) no activity, 2) sporadic-small numbers of laboratoryconfirmed influenza cases or a single influenza outbreak reported but no increase in cases of influenza-like illness (ILI), 3) local-outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza in a single region of a state, 4) regional-outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza in at least two but less than half the regions of a state, and 5) widespread-outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza in at least half the regions of a state. 2004 † . During the latest reporting week, ending January 3, health departments in 38 states, the District of Columbia, and New York City reported widespread influenza activity. Nine states reported regional activity, one state reported local activity, and one state and Guam reported sporadic activity (Figure 1 ). The percentage of outpatient visits for influenzalike illness (ILI) § decreased in all surveillance regions during the week ending January 3, with an overall national percentage of 6.2%. This percentage is above the national baseline ¶ of 2.5%. The percentage of specimens testing positive for influenza also decreased; however, the percentage of deaths attributed to pneumonia and influenza (P&I) increased.
Laboratory Surveillance
During 
P&I Mortality Surveillance
During the reporting week of December 21-December 27, 2003, P&I accounted for 9.0% of all deaths reported through the 122 Cities Mortality Reporting System and increased to 9.4% during the reporting week of December 28, 2003-January 3, 2004. The epidemic threshold † † was 7.9% and 8.0% for each reporting week, respectively (Figure 2 ).
ILI Surveillance
The percentage of patient visits § § to approximately 1,000 U.S. sentinel providers nationwide for ILI decreased from 8.8% during the week ending December 27 to 6.2% for the week ending January 3, but remained above the national baseline Mortality Reporting System is projected by using a robust regression procedure that applies a periodic regression model to the observed percentage of deaths from P&I during the preceding 5 years; the epidemic threshold is 1.645 standard deviations above the seasonal baseline percentage. § § National and regional percentage of patient visits for ILI are weighted on the basis of state population. of 2.5% ( Figure 3 ). The percentage of patient visits for ILI decreased in all nine surveillance regions ¶ ¶ during the week ending January 3. On a regional level, the percentage of visits for ILI was highest in the West South Central region (8.3%), followed by Pacific region (7.1%), East North Central region (6.8%), South Atlantic region (6.4%), Mid-Atlantic region (6.2%), East South Central region (4.8%), New England region (4.6%), West North Central region (4.5%), and the Mountain region (3.4%).
Activity Reported by State and Territorial Epidemiologists
During the week ending January 3, influenza activity was reported as widespread in 38 states (Alabama, Alaska, Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Jersey, New York, North Carolina, North Dakota, Ohio, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Wisconsin, and Wyoming), the District of Columbia, and New York City. Regional activity was reported in nine states (Colorado, Idaho, Kansas, Kentucky, Louisiana, Nebraska, New Hampshire, Washington, and West Virginia). Oklahoma reported local activity, and New Mexico and Guam reported sporadic activity. Oregon did not report. During the week ending December 27, health departments in 42 states, the District of Columbia, and New York City reported widespread influenza activity, and eight states reported regional activity.
Weekly updates on influenza activity will be published in MMWR during the influenza season. Additional information about influenza activity is available from CDC at http:// www.cdc.gov/flu. Alaska  3  2  ----2  2  9  12  Hawaii  22  40  ---1  1  3  12  25 Guam 
